Anavex Life Sciences (AVXL) EBITDA (2016 - 2025)

Anavex Life Sciences (AVXL) has 10 years of EBITDA data on file, last reported at -$5.7 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 58.34% year-over-year to -$5.7 million; the trailing twelve-month figure through Dec 2025 stood at -$43.5 million (up 21.08% YoY), and the FY2025 full-year result was -$51.4 million, up 2.78% from the prior year.
• EBITDA advanced to -$5.7 million in Q4 2025, from -$10.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $195.1 million in Q2 2021 to a low of -$15.4 million in Q4 2022.
• A 5-year average of $11.1 million and a median of -$12.6 million in 2024 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 4315.69% in 2021, while the deepest fall reached 184.78% in 2021.
• Tracing AVXL's EBITDA over 5 years: stood at -$11.7 million in 2021, then slumped by 31.22% to -$15.4 million in 2022, then rose by 26.04% to -$11.4 million in 2023, then slipped by 19.46% to -$13.6 million in 2024, then surged by 58.34% to -$5.7 million in 2025.
• Business Quant data shows AVXL's EBITDA at -$5.7 million in Q4 2025, -$10.8 million in Q3 2025, and -$14.5 million in Q2 2025.